fluorocyclopentenylcytosine

Small moleculeexperimental

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2013 (NCT02030067)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • fluorocyclopentenylcytosine
  • rx-3117
  • rx-3117
  • rx-3117
  • tv-1360

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03189914Phase 1/Phase 2 (Phase 2)Jun 1, 2017Rexahn Pharmaceuticals, Inc.
NCT02030067Phase 1/Phase 2 (Phase 2)Dec 1, 2013Rexahn Pharmaceuticals, Inc.
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Rexahn Pharmaceuticals, Inc.For profit2212013
1 organizations
Page 1 / 1